The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: Results from the GIANT trial

Journal of Clinical Psychopharmacology

Volumn 34, Issue 2, 2014, Pages 190-198

  Schoemaker, Joep H ^a,b   Jansen, Wim T ^a   Schipper, Jacques ^a   Szegedi, Armin ^c  

^a NV ORGANON   (Netherlands)

^b SYNEOS HEALTH   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Glycine transporter inhibitor; Negative symptoms; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; GLYCINE RECEPTOR ANTAGONIST; GLYCINE TRANSPORTER 1; N METHYL N (6 METHOXY 1 PHENYL 1,2,3,4 TETRAHYDRONAPHTHALEN 2 YLMETHYL)AMINO METHYLCARBOXYLIC ACID; ORG 25935; PLACEBO; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ANXIETY; ARTICLE; BLURRED VISION; CALGARY DEPRESSION SCALE; COGNITION; CONTROLLED STUDY; CONVULSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOOT FRACTURE; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCALE FOR ASSESSMENT OF NEGATIVE SYMPTOM; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VISUAL FIELD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896404591     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000073     Document Type: Article

References (36)

1. Buchanan RW. Persistent negative symptoms of schizophrenia: an overview. Schizophr Bull. 2007;33: 1013-1022.
2. Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry. 2006;67(suppl 9): 9-13.
3. Insel TR. Rethinking schizophrenia. Nature. 2010;468;187-193.
4. Goff DC, Coyle JT. The merging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001;158: 1367-1377.
5. Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptorYmediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16: 522-537.
6. Javitt DC. Glycine transporters and the treatment of schizophrenia. Biol Psychiatry. 2008;63: 6-8.
7. Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel. 2009;12: 468-478.
8. Sur C, Kinney GG. The therapeutic potential of glycine transposter-1 inhibitors. Expert Opin Investig Drugs. 2004;13: 515-521.
9. Walker GB, Hamilton W, Ge J, et al. Org 25935: a selective glycine uptake inhibitor. Schizophr Res. 2001;49(suppl 1): 97.
10. Mezler M, Hornberger W, Mueller R, et al. Inhibitors of GlyT1 affect glycine transport via discrete binding sites. Mol Pharmacol. 2008;74(6): 1705-1715.
11. Ge J, Hamilton W, Shahid M, et al. The effects of Org 25935 on the extracellular levels of glycine in brain regions of freely moving rats using microdialysis. Br J Pharmacol. 2001;133(ProcSuppl): 135P.
12. Lidö HH, Stomberg R, Fagerberg A, et al. The glycine uptake inhibitor Org 25935 interacts with basal and ethanol-induced dopamine release in rat nucleus accumbens. Alcohol Clin Exp Res. 2009;33: 1151-1157.
13. Kleijn HJ, Gerrits MGF, Schoemaker JH, et al. PK-PD modelling and simulation of phase I data to support development of a new compound in the field of CNS. Presented at the 5th International Symposium on Measurement and Kinetics of In Vivo Drug Effects, April 26-29, 2006, Noordwijkerhout, the Netherlands.
14. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13: 261-276.
15. Addington D, Addington J, Maticka-Tyndle E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;(22): 39-44.
16. Chouinard G, Annable L, Jones BD. The extrapyramidal symptom rating scale. Can J Neurol Sci. 1980;7: 233-248.
17. Lindenmayer JP, Czobor P, Alphs L, et al. InterSePT Study Group. The InterSePT scale for suicidal thinking reliability and validity. Schizophr Res. 2003;63: 161-170.
18. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982;39: 784-788.
19. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58: 538-546.
20. Buchanan RW, Heinrichs DW. The neurological evaluation scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res. 1989;27: 335-350.
21. Ferris FL 3rd, Kassoff A, Bresnick GH, et al. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94: 91-96.
22. Beck RW, Bergstrom TJ, Lichter PR. A clinical comparison of visual field testing with a new automated perimeter, the Humphrey Field Analyzer, and the Goldmann perimeter. Ophthalmology. 1985;92: 77-82.
23. Bowman KJ. A method for quantitative scoring of the Farnsworth Panel D-15. Acta Ophthalmologica. 1982;60: 907-916.
24. Schoemaker J, Gaur R, Chawla V, et al. Expert Rater Assisted Score Evaluation (ERASE): a new method to increase efficiency in drug development programs. Presented at the 22nd ECNP Congress, September 12-16, 2009, Istanbul, Turkey.
25. Schoemaker J. Accurate method to assess disease severity in clinical trials concerning psychopathology. European patent application no. EP 1 974 661 A1, Bulletin 2008/40, October 1, 2008; US patent application no. US 2009/0024003 A1, January 22, 2009; Japan patent application no. P2008-251006A, October 16, 2008.
26. Möller HJ, Müller H, Borison RL, et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 1995;245: 45-49.
27. Merriam AE, Kay SR, Opler LA, et al. Neurological signs and the positive-negative dimension in schizophrenia. Biol Psychiatr. 1990;28: 181-192.
28. Smith RC, Kadewary RP. Neurological soft signs and response to risperidone in chronic schizophrenia. Biol Psychiatr. 1996;40: 1056-1059.
29. Smith RC, Kadewari RP, Rosenberger JR, et al. Nonresponding schizophrenia: differentiation by neurological soft signs and neuropsychological tests. Schizophr Bull. 1999;25: 813-825.
30. Goff D, Herz L, Posever T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology. 2005;179: 144-150.
31. Evins AE, Fitzgerald SM, Wine L, et al. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry. 2000;157: 826-828.
32. Marx CE, Keefe RSE, Buchanan RW, et al. Proof-of-concept trial with the neurosteroid pregnolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology. 2009;34: 1885-1903.
33. Joffe G, Terevnikov V, Joffe M, et al. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res. 2009;108: 245-251.
34. Umbricht D, Yoo K, Youssef E, et al. Investigational glycine transporter type 1 (GlyT1) inhibitor RG1678: results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Presented at the 49th ACNP Annual Meeting, December 5-9, 2010, Miami Beach, FL.
35. Alberati D, Moreau JL, Lengyel J, et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology. 2012;62(2): 1152-1161.
36. Kleijn HJ, Gerrits MGF, Schoemaker JH, de Greef HJMM. PK-PD modeling and simulation of phase I data to support development of a new compound in the field of CNS. Presented at the 5th International Symposium on Measurement and Kinetics of In Vivo Drug Effects, April 26-29, 2006, Noordwijkerhout, the Netherlands.